Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AZD1222
Description:
A viral-vector vaccine developed to prevent COVID-19, also known as ChAdOx1 nCoV-19 and Vaxzevria.
Primary topic:
SARS-CoV-2 and COVID-19 Research (35%)
Related topics:
SARS-CoV-2 and COVID-19 Research (35%),
Heparin-Induced Thrombocytopenia and Thrombosis (11%),
Pharmacovigilance and Adverse Drug Reactions (9%)
Wikidata ID:
wiki/Q95042269
OpenAlex ID:
keywords/azd1222
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
2020
·
Merryn Voysey
, Sue Ann Costa Clemens
, et al.
·
The Lancet
·
5,092
PDF
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
2020
·
Maheshi N Ramasamy
, Angela M Minassian
, et al.
·
The Lancet
·
1,551
PDF
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
2021
·
Merryn Voysey
, Sue Ann Costa Clemens
, et al.
·
The Lancet
·
1,201
PDF
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
2021
·
Thibault Fiolet
, Yousra Kherabi
, et al.
·
Clinical Microbiology and Infection
·
1,024
PDF
Oxford–AstraZeneca COVID-19 vaccine efficacy
2020
·
Maria Deloria Knoll
, Chizoba Wonodi
·
The Lancet
·
798
PDF
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
2021
·
Katherine R. W. Emary
, Tanya Golubchik
, et al.
·
The Lancet
·
677
PDF
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
2020
·
Katie J. Ewer
, Jordan R. Barrett
, et al.
·
Nature Medicine
·
636
PDF
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
2020
·
Omna Sharma
, Ali A. Sultan
, et al.
·
Frontiers in Immunology
·
623
PDF
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
2022
·
Sue Ann Costa Clemens
, Lily Weckx
, et al.
·
The Lancet
·
456
PDF
Review of COVID-19 vaccine subtypes, efficacy and geographical distributions
2021
·
Andre Ian Francis
, Saudah Ghany
, et al.
·
Postgraduate Medical Journal
·
343
PDF
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
2020
·
Jordan R. Barrett
, Sandra Belij-Rammerstorfer
, et al.
·
Nature Medicine
·
338
PDF
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022
2023
·
Nana Wu
, Keven Joyal-Desmarais
, et al.
·
The Lancet Respiratory Medicine
·
332
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
2021
·
Amy Flaxman
, Natalie G Marchevsky
, et al.
·
The Lancet
·
267
PDF
Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222)
2021
·
Gustavo C. Román
, Fernando Gracia
, et al.
·
Frontiers in Immunology
·
256
PDF
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents
2022
·
Øystein Karlstad
, Petteri Hovi
, et al.
·
JAMA Cardiology
·
254
PDF
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases
2021
·
A. Català
, C. Muñoz-Santos
, et al.
·
British Journal of Dermatology
·
245
PDF
COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
2021
·
Piero Olliaro
, Els Torreele
, et al.
·
The Lancet Microbe
·
241
PDF
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
2021
·
John Frater
, Katie J Ewer
, et al.
·
The Lancet HIV
·
237
PDF
One year update on the COVID-19 pandemic: Where are we now?
2020
·
Sanjay Kumar Mishra
, Timir Tripathi
·
Acta Tropica
·
223
PDF
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study
2022
·
Alejandro Jara
, Eduardo A Undurraga
, et al.
·
The Lancet Global Health
·
211
PDF
Vaccine Effectiveness of the First Dose of ChAdox1 nCOV-19 and BNT162b2 Against SARS-CoV-2 Infection in Residents of Long Term Care Facilities (VIVALDI Study)
2021
·
Madhumita Shrotri
, Maria Krutikov
, et al.
·
The Lancet Infectious Diseases
·
196
PDF
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
2021
·
Annika Fendler
, Scott T. C. Shepherd
, et al.
·
Nature Cancer
·
189
PDF
Prothrombotic immune thrombocytopenia after COVID-19 vaccination
2021
·
Andreas Tiede
, Ulrich J. Sachs
, et al.
·
Blood
·
183
PDF
Association of SARS-CoV-2 Vaccination During Pregnancy With Pregnancy Outcomes
2022
·
Maria C. Magnus
, Anne K. Örtqvist
, et al.
·
JAMA
·
171
PDF
Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
2021
·
Piotr Rzymski
, Barbara Poniedziałek
, et al.
·
Vaccines
·
170
PDF
Show more works
View as search
Works count:
1,591
Citation count:
23,970
Year
Topic
Type